AVEO Pharmaceuticals, Inc. (NASDAQ:AVEO) Files An 8-K Regulation FD DisclosureItem 7.01.
From time to time, we conduct meetings with third parties in which we utilize a corporate slide presentation. The slide presentation that we expect to utilize in our January11, 2018 presentation, and related meetings, at the Annual J.P. Morgan Healthcare Conference is attached as Exhibit 99.1 to this Current Report on Form 8-K and is incorporated herein by reference.
The presentation includes an update to our estimated timeline for reporting topline results from the TIVO-3 trial of tivozanib in third-line refractory renal cell carcinoma. We expect to report TIVO-3 topline data, including progression free survival and the trend in overall survival, in the second quarter of 2018.
The presentation also includes other clinical, development, collaboration and financial updates, including the previously reported cash flow impact of the refinancing of our existing debt facility with Hercules Capital, Inc. and its affiliates. The terms of the refinancing enable approximately an additional $12.1million in cash flow over 2018 and 2019, when compared with the prior loan, and are expected to extend our cash runway into 2019. For the complete terms of the Amended and Restated Loan and Security Agreement, dated December28, 2017, by and among the Company and the parties thereto, see our Current Report on Form 8-K filed with the Securities and Exchange Commission on January2, 2018.
We may amend or update this information at any time and from time to time through another Current Report on Form 8-K, a later company filing, or other means.
The information in this Item 7.01 and in Exhibit 99.1 shall not be deemed “filed” for purposes of Section18 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”) or otherwise subject to the liabilities of that section, nor shall it be deemed incorporated by reference in any filing under the Securities Act of 1933, as amended, or the Exchange Act, except as expressly set forth by specific reference in such a filing.
| Item 7.01. | Financial Statements and Exhibits. |
| 99.1 | Corporate Presentation Slide Deck dated January 2018 |
AVEO PHARMACEUTICALS INC ExhibitEX-99.1 2 d517845dex991.htm EX-99.1 EX-99.1 AVEO Overview 36th Annual JP Morgan Healthcare Conference Exhibit 99.1 Forward-Looking Statements This presentation contains forward-looking statements that involve substantial risks and uncertainties. All statements,…To view the full exhibit click here
About AVEO Pharmaceuticals, Inc. (NASDAQ:AVEO)
AVEO Pharmaceuticals, Inc. is a biopharmaceutical company. The Company’s platform delivers insights into cancer and related disease. The Company’s product candidates include Tivozanib, Ficlatuzumab, AV-203 and AV-380. Tivozanib is a selective long half-life vascular endothelial growth factor tyrosine kinase inhibitor (VEGF TKI) that inhibits over three VEGF receptors. Tivozanib is designed to optimize VEGF blockade while minimizing off-target toxicities. Ficlatuzumab is a Hepatocyte Growth Factor (HGF) inhibitory antibody. AV-203 is an anti-ErbB3 monoclonal antibody with ErbB3 affinity. Its preclinical studies suggest that neuregulin1 (NRG1) levels predict AV-203 antitumor activity in preclinical models. AV-380 is a humanized Immunoglobulin G 1 (IgG1) inhibitory monoclonal antibody. AV-380 targets growth differentiating factor 15 (GDF15).
